XML 34 R53.htm IDEA: XBRL DOCUMENT v2.4.0.8
Significant Agreements - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
 1 Months Ended 12 Months Ended
Jan. 31, 2014
Aug. 31, 2013
Aug. 31, 2012
Aug. 31, 2013
R-Pharm CJSC [Member]
Dec. 31, 2013
Elanco Animal Health [Member]
Dec. 31, 2013
Elanco Animal Health [Member]
First Two Years [Member]
Dec. 31, 2013
Elanco Animal Health [Member]
Second Two Years [Member]
Dec. 31, 2013
Elanco Animal Health [Member]
U.S. [Member]
Dec. 31, 2013
Elanco Animal Health [Member]
European Union [Member]
Schedule of Other Related Party Transactions [Line Items]                  
Upfront payment received $ 500 $ 1,500 $ 313 $ 1,500          
Development milestone payment       3,000 1,500        
Sales-based payments       15,000          
Deferred revenue recognition period 48 months 70 months 6 months 70 months          
Fees for multi-year contract research and development services           2,750 3,000    
Payment for first US regulatory approval         2,000        
Payment for first commercial sale of product               4,000 1,500
Payment for reaching specified annual sales         $ 15,000